Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,931 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07114614Recruiting
Fatty acid proteins and cell aging in cancer survivors
This study looks at certain proteins and signs of cell aging in cancer survivors. It may help understand how past cancer treatments affect the body over time.
Cleveland, OhioAges 5–50 - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07109440Recruiting
FAPI PET/CT scan for colorectal cancer liver spread
This study uses a special type of PET/CT scan (FAPI) to get a better look at the environment around colorectal cancer that has spread to the liver. It may help doctors learn more about the tumor and plan treatment.
BrusselsAges 18 years+ - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT07108348Recruiting
ADAR1 levels in rectal cancer
This study looks at a protein called ADAR1 in rectal cancer tissue. It aims to see how ADAR1 levels might be related to the cancer and help doctors understand the disease better.
Konya, MeramAges 18–90 - NCT07113275RecruitingPhase 3
Short versus long radiation schedule for advanced rectal cancer
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Wuhan, HubeiAges 18–75 - NCT07106424Recruiting
Early screening study for multiple gastrointestinal tumors
This study is looking for people aged 40-75 who have never had cancer to participate in early screening for gastrointestinal tumors. The goal is to find cancers early when they are easier to treat.
Jinan, ShandongAges 40–75 - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT05795244RecruitingPhase 2
Nivolumab for resected mismatch-repair deficient endometrial cancer
This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.
SeoulAges 20 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT02495337Recruiting
Collecting tissue samples during stomach or esophagus procedures
This study collects small tissue samples from people who already need an endoscopy (EGD) and/or surgery for esophagus or stomach-related problems. The goal is to help researchers learn more about gastroesophageal cancers and related conditions.
Toronto, OntarioAges 18 years+ - NCT02971358Recruiting
Surgery for very high-risk or limited-spread prostate cancer
This trial looks at how safe and how well early prostate surgery works for men with newly diagnosed very high-risk prostate cancer or a limited number of metastases (cancer spread). It may help some people live longer and control the cancer, but eligibility is very specific.
ViennaAges 18–75 - NCT07104604RecruitingPhase 2
New combo before surgery for low rectal cancer
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Shantou, GuangdongAges 18–75 - NCT07105631Recruiting
Study of cediranib and immunotherapy in advanced colorectal cancer
This study looks at how patients with a certain type of advanced colorectal cancer (MSS-type) feel and do during treatment with a combo of cediranib and immunotherapy. It aims to learn about side effects, quality of life, and how well the treatment works in everyday practice.
Chengdu, SichuanAges 18 years+ - NCT07101302Recruiting
App-based insomnia help for cancer survivors
This trial tests a smartphone app designed to help cancer survivors improve their sleep. If you have trouble sleeping and live in Canada, this app-based program could help you manage insomnia without needing to visit a clinic.
St. John's, Newfoundland and LabradorAges 18 years+ - NCT07103395RecruitingPhase 2
Study of chemo, radiation, and dual immunotherapy for stage 3 lung cancer
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
Guangzhou, GuangdongAges 18–75 - NCT07104266RecruitingPhase 2
Celecoxib for early triple-negative breast cancer
This research study tests whether adding a drug called celecoxib (an anti-inflammatory pill) can help treat early-stage triple-negative breast cancer after surgery, before or during radiation therapy. You may be eligible if your cancer was removed cleanly and you do not have other health issues like stomach ulcers, kidney problems, or a history of allergic reactions to certain pain relievers.
Sherbrooke, QuebecAges 18 years+ - NCT07104214Recruiting
Predicting stomach retention risk before sedated endoscopy
This study is building a tool to predict if a patient's stomach will empty normally before a sedated upper endoscopy (gastroscopy). It tests risk factors that help doctors plan safer procedures.
Hangzhou, ZhejiangAges 18 years+ - NCT07097155Recruiting
Avocados and cell aging in breast cancer survivors
This study tests whether eating avocados regularly can affect how your cells age. It is for women who have finished treatment for early-stage breast cancer and currently eat fewer than 2 avocados per week.
Reus, TarragonaAges 40–65 - NCT07096180Recruiting
Integrative Chinese and Western Medicine for Breast Cancer
This study looks at combining traditional Chinese medicine with Western medical care for women with breast cancer. It aims to see how integrative approaches might help people undergoing standard treatments.
New Taipei CityAges 18 years+ - NCT07102901RecruitingPhase 2
Study of SHR2554 with other therapies for gastric or junction cancer
This trial tests a new drug, SHR2554, combined with other anticancer treatments for advanced stomach or gastroesophageal junction cancer. It aims to see if the combination is safe and effective. You may qualify if you have measurable disease and are generally in good health.
Harbin, HeilongjiangAges 18–75 - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT07098338RecruitingPhase 2
New drug combos for advanced lung cancer
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
Santa Monica, CaliforniaAges 18 years+ - NCT04358913Recruiting
MRI scan study during radiation treatment planning
This study looks at how an MRI scanner can be used alongside a radiation treatment machine to plan therapy. It may help improve how radiation is targeted, though joining is mainly about whether you can safely and comfortably complete the MRI scans.
Edmonton, AlbertaAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,931 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.